CDMO collaborates with synthetic DNA provider for biologic drug development

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ gorodenkoff)
(Image: Getty/ gorodenkoff)

Related tags: Biologics, Drug development, Dna, Antibody, discovery services, Oncology, Pain

Twist Bioscience, a synthetic DNA provider, enters a strategic collaboration with LakePharma to bolster antibody discovery and optimization for biologic drug development.

Per the agreement, customers of the contract development and manufacturing organization (CDMO), LakePharma, will have access to Twist’s antibody discovery and optimization platforms as a service offering.

One of these platforms has the capability to generate therapeutic antibodies against a class of protein drug targets known as G Protein-coupled receptors (GPCRs), which have been investigated for the involvement in multiple disease classes such as inflammation, cancer, metabolism, respiratory, and pain.

According to the Twist spokesperson, through the partnership the companies “may be able to expedite discovery and development timelines while beginning with improved antibody therapeutics.”

The spokesperson told us that the company “writes DNA from scratch,”​ enabling it to create any specific combination and premutation, which cannot be created using traditional random mutagenesis library development as that typically misses large sections or overrepresents others.

Additionally, Twist can synthesize DNA libraries for any given target, a strength that will be leveraged with LakePharma’s integrated discovery and development services.

Twist invested $50m (€44.57m) in April 2018 to advance its silicon-based DNA Synthesis Platform​ which can be used to support drug discovery, as well as next-generation sequencing for target enrichment and detection of disease-causing genetic variations. 

Related news

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Discover Fermion’s new API unit 4 in Hanko

Discover Fermion’s new API unit 4 in Hanko

Recorded the 04-Sep-2018 | Webinar

Join this webinar to learn more about Fermion’s new manufacturing unit 4 at the Hanko site. This webinar will provide virtual tour to our new state of...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars